Inventor · disambiguated record
Robert Mazzola
Also filed as: MAZZOLA JR ROBERT D · MAZZOLA ROBERT · MAZZOLA ROBERT D
34 granted patents·6 pending applications·156 citations·filing 2002–2019
96Inventor score
Top patents by PatentIndex Score
40 records- 0195US7763609B2Heterocyclic aspartyl protease inhibitorsSCHERING CORP·Filed 2007·Granted Jul 27, 2010·38 cites·12 claims
- 0289US10351564B26,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptorMERCK SHARP & DOHME·Filed 2018·Granted Jul 16, 2019·7 cites·27 claims
- 0388US7700603B2Heterocyclic aspartyl protease inhibitorsSCHERING CORP·Filed 2005·Granted Apr 20, 2010·9 cites·8 claims
- 0487US10329289B26,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptorBAO JIANMING·Filed 2016·Granted Jun 25, 2019·10 cites·20 claims
- 0586US8829036B2Heterocyclic aspartyl protease inhibitorsZHU ZHAONING·Filed 2012·Granted Sep 9, 2014·7 cites·3 claims
- 0686US7973067B2Heterocyclic aspartyl protease inhibitorsSCHERING CORP·Filed 2008·Granted Jul 5, 2011·6 cites·22 claims
- 0785US8691831B2Heterocyclic aspartyl protease inhibitorsZHU ZHAONING·Filed 2012·Granted Apr 8, 2014·7 cites·18 claims
- 0885US8691833B2Heterocyclic aspartyl protease inhibitorsZHU ZHAONING·Filed 2012·Granted Apr 8, 2014·7 cites·9 claims
- 0984US10933056B23-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptorMERCK SHARP & DOHME·Filed 2019·Granted Mar 2, 2021·2 cites·11 claims
- 1084US7592348B2Heterocyclic aspartyl protease inhibitorsSCHERING CORP·Filed 2004·Granted Sep 22, 2009·16 cites·41 claims
- 1182US7652020B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2005·Granted Jan 26, 2010·5 cites·48 claims
- 1278US11149036B23-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptorACTON III JOHN J·Filed 2018·Granted Oct 19, 2021·3 cites·18 claims
- 1378US8927559B2Quinazolinone-type compounds as CRTH2 antagonistsASLANIAN ROBERT G·Filed 2011·Granted Jan 6, 2015·6 cites·16 claims
- 1478US8518975B2Gamma secretase modulatorsASLANIAN ROBERT G·Filed 2008·Granted Aug 27, 2013·5 cites·15 claims
- 1578US6838466B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2002·Granted Jan 4, 2005·10 cites·41 claims
- 1677US8242112B2Heterocyclic aspartyl protease inhibitorsZHU ZHAONING·Filed 2011·Granted Aug 14, 2012·2 cites·4 claims
- 1774US10981902B25-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptorMERCK SHARP & DOHME·Filed 2018·Granted Apr 20, 2021·1 cites·18 claims
- 1874US8178513B2Heterocyclic aspartyl protease inhibitorsZHU ZHAONING·Filed 2009·Granted May 15, 2012·1 cites·13 claims
- 1974US8168641B2Aspartyl protease inhibitorsWU YUSHENG·Filed 2007·Granted May 1, 2012·2 cites·21 claims
- 2072US10945771B2Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptorMERCK SHARP & DOHME·Filed 2018·Granted Mar 16, 2021·2 cites·18 claims
- 2172US9469615B2Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulatorsBOYCE CHRISTOPHER W·Filed 2011·Granted Oct 18, 2016·4 cites·27 claims
- 2271US10836775B26,6-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptorMERCK SHARP & DOHME·Filed 2017·Granted Nov 17, 2020·1 cites·13 claims
- 2370US8722708B2Substituted isoindolines as aspartyl protease inhibitorsSTAMFORD ANDREW·Filed 2006·Granted May 13, 2014·2 cites·9 claims
- 2470US8357682B2Gamma secretase modulatorsZHU ZHAONING·Filed 2008·Granted Jan 22, 2013·1 cites·37 claims
- 2569US8629155B2Aspartyl protease inhibitorsWU YUSHENG·Filed 2012·Granted Jan 14, 2014·1 cites·6 claims
- 2662US7504391B2Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disordersSCHERING CORP·Filed 2004·Granted Mar 17, 2009·1 cites·26 claims
- 2761US8778980B2Heterocyclic aspartyl protease inhibitorsZHU ZHAONING·Filed 2012·Granted Jul 15, 2014·0 cites·15 claims
- 2855US7598242B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2005·Granted Oct 6, 2009·0 cites·3 claims
- 2954US7034057B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2003·Granted Apr 25, 2006·0 cites·2 claims
- 3051US2010298381A1Gamma secretase modulatorsSCHERING CORP·Filed 2008·Application pending·0 cites
- 3150US2011027264A1Gamma secretase modulators for the treatment of alzheimer's diseaseHUANG XIANHAI·Filed 2009·Application pending·0 cites
- 3250US2011009392A1Gamma secretase modulatorsSCHERING CORP·Filed 2008·Application pending·0 cites
- 3350US2011053918A1Gamma secretase modulatorsZHU ZHAONING·Filed 2008·Application pending·0 cites
- 3449US11970479B23-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptorMERCK SHARP & DOHME LLC·Filed 2019·Granted Apr 30, 2024·0 cites·18 claims
- 3546US7879997B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2006·Granted Feb 1, 2011·0 cites·9 claims
- 3644US11339156B23-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptorMERCK SHARP & DOHME·Filed 2018·Granted May 24, 2022·0 cites·11 claims
- 3742US11230556B26,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptorMERCK SHARP & DOHME·Filed 2017·Granted Jan 25, 2022·0 cites·11 claims
- 3841US2014378416A1Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseasesDWYER MICHAEL P·Filed 2012·Application pending·0 cites
- 3941US2015057246A1Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseasesDWYER MICHAEL P·Filed 2012·Application pending·0 cites
- 4039US11319298B2Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptorMERCK SHARP & DOHME·Filed 2017·Granted May 3, 2022·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when Robert Mazzola files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →